Chief Executive Officer and Co-Founder
Chief Science Officer and Co-Founder
Michael Johnson, PhD
- Forbes 30 Under 30 – 2019
- NJ BIZ 40 Under 40 – 2021
- NJ BIZ 2021 Next Generation of Leaders – 2021
- Muhlenberg College Alumni Achievement Award
- TEDx Speaker
- 1 Awarded Patent
Tom Villani, PhD
- 2 NIH/NSF Phase II SBIR Grants
- 4 NIH/NSF Phase I SBIR Grants
- 2 Awarded Patents
- Invented Visikol HISTO technology
- Invented Visikol Multiplex IF technology
- Developed and built 3Screen and BitSlide software
Visikol is a contract research services company that is focused on accelerating the drug discovery and development process through providing its clients with advanced tissue imaging and advanced cell culture services. Today, Visikol counts the top twenty pharmaceutical companies as clients and has been instrumental in dozens of drug discovery programs.
The company provides end-to-end services that include 3D tissue imaging, multiplex tissue imaging, digital pathology, high content imaging, 2D cell culture assays, 3D cell culture assays and ex vivo tissue slice assays. Visikol’s expertise lies in both transforming tissues into actionable insights as well as bridging the gap between in vitro assays and in vivo results through the use of best-in-class cell culture models.
In addition to its services, Visikol sells a suite of tissue clearing reagents and kits as well as the HUREL® Micro Liver portfolio of primary hepatocyte liver models.
What makes us different?
Visikol differentiates itself through its expertise in advanced imaging and image analysis, 3D cell culture models and AI-enhanced digital pathology. The Visikol team has several patented and proprietary technologies for tissue imaging, tissue processing, and image analysis. Utilizing a suite of tools custom developed for image processing, the Visikol team uses advanced automated and AI-enhanced image processing techniques to quantitatively analyze bioimaging data. We work closely with our Clients as an extension of their drug discovery team and work to develop customized research plans that best address their specific research question.
How we started
The inspiration for Visikol began at Rutgers University in the fall of 2012 when Visikol Co-Founder Dr. Tom Villani first developed the Visikol tissue clearing reagents for use with a wide range of tissues. These reagents have been used by hundreds of research groups from all around the world from the jungles of Rwanda, researchers in the Arctic Circle, to researchers at major research institutions such as La Jolla Institute for Allergy and Immunology, Cedars-Sinai, Harvard, University of Pennsylvania, and NIH. Today, Visikol has developed into a leading contract research services business that leverages its expertise in imaging, image analysis and advanced in vitro models to provide best-in-class services to its pharmaceutical and biotech Clients.
Visikol joined the BICO family through acquisition in 2021.
Founded in 2016, BICO (formerly CELLINK) is the world’s leading bioconvergence company, organized into three business areas: Biosciences, Bioautomation, and Bioprinting. BICO aims to reduce the organ shortage and speeds up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry.
Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people’s health and lives.
We have over 32,000 installed instruments in more than 3,500 laboratories, including the top 20 pharmaceutical companies. They are being used in more than 65 countries, and have been cited in more than 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO.